RxDoctor Payments Data

Sandra Brown, APRN

Family · Hopkinsville, KYNPI 1932509270

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 67 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$756
  • Phathom Pharmaceuticals, Inc.$174
  • Sumitomo Pharma America, Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Novartis$95
  • Novo Nordisk$38
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$1,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$10,622
Medicare patients
32
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$37,959
LinzessLinaclotide38$25,875
JardianceEmpagliflozin18$17,069
EliquisApixaban11$7,546
Atorvastatin Calcium113$789
Albuterol Sulfate HfaAlbuterol Sulfate36$742
Ropinirole Hcl25$583
Omeprazole52$523
Levothyroxine Sodium62$454
Hydroxyzine Pamoate38$415
Losartan Potassium42$414
Ezetimibe12$395
Ammonium Lactate13$372
Gabapentin41$343
Famotidine18$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$37,95940 claims
AbbVieLinzess$756$25,87538 claims
PfizerEliquis$19$7,54611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.

Other family in Hopkinsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →